ASCO GU 2021 Prostate Cancer - Results from #20

Viewing 21-40 of 83 articles

ASCO GU 2021: Dose-intensification among Patients Receiving Salvage RT Following Radical Prostatectomy and the Clinical Cell-cycle Risk Score to Identify Men Who Can Forgo ADT at the Time of Dose-Escalated RT for Prostate Cancer - Discussion

ASCO GU 2021: Association of the Clinical Cell-Cycle Risk Score with Metastasis After Radiation Therapy and Identification of Men with Prostate Cancer Who Can Forgo Combined ADT

ASCO GU 2021: Multimodal Biomarkers Overcome Sampling Bias to Predict Presence of Aggressive Localized Prostate Cancer

ASCO GU 2021:The Stereotactic Prostate Radiotherapy (SPORT) Trial: A Randomized Feasibility Study Comparing Prostate SABR to Prostate and Pelvic Nodal SABR

ASCO GU 2021: Lighting the Way: Lutetium in the Treatment Paradigm

ASCO GU 2021: Analysis of the Effect of Crossover from Placebo to Darolutamide on Overall Survival Benefit in the ARAMIS Trial

ASCO GU 2021: The Landscape of Genetic Alterations Using ctDNA-based Comprehensive Genomic Profiling in Patients with Advanced Prostate Cancer

ASCO GU 2021: Rucaparib plus Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: Pharmacokinetics and Safety Data from the Phase Ib RAMP Study

ASCO GU 2021: Association of Reductions in PSA Screening Across States with Increased Metastatic Prostate Cancer in the United States

ASCO GU 2021: Timing of High-Dose Rate Brachytherapy with External Beam Radiotherapy in Intermediate and High-Risk Localized Prostate Cancer (THEPCA) Patients and Its Effects on Toxicity and Quality of Life: Results of a Randomized Feasibility Trial

ASCO GU 2021: Dose-Intensified Versus Conventional Dose-Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Six-Year Outcomes of the SAKK 09/10 Randomized Phase III Trial

ASCO GU 2021: Best of Journals: Prostate Cancer - Surgery

ASCO GU 2021: Best of Journals: Prostate Cancer - Radiation Oncology

ASCO GU 2021: Phase IIB Trial of Oral ModraDoc006/r as a Tolerable and Effective Option in Comparison with Intravenous Docetaxel in Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2021: Randomized Phase II Trial of Radium-223 Plus Enzalutamide vs Enzalutamide Alone in Metastatic Castration-Refractory Prostate Cancer: Final Efficacy and Safety Results

ASCO GU 2021: Progress and Promise in Treatment Personalization for Advanced Prostate Cancer Panel Discussion

ASCO GU 2021: Beyond the Basics: Harnessing the Immune System to Fight Prostate Cancer

ASCO GU 2021: Clinically Significant Events Associated with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treatments

ASCO GU 2021: Clinical Conundrums of Genomically Driven Prostate Cancer - Case Panel Discussion

ASCO GU 2021: Phase IIb Trial of Oral ModraDoc006/ritonavir as a Tolerable and Effective Option in Comparison with Intravenous Docetaxel in mCRPC

1
2
3
4
5